<DOC>
	<DOCNO>NCT00278421</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . It yet know schedule rituximab combination chemotherapy effective treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two different schedule rituximab combination chemotherapy compare well work treat patient aggressive B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy 2 different schedule immunochemotherapy comprise rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone patient previously untreated , low-risk , aggressive B-cell non-Hodgkin 's lymphoma . - Compare acute chronic side effect patient treat regimen . - Compare time treatment failure patient treat regimen . Secondary - Compare time progression patient treat regimen . - Compare overall disease-free/relapse-free survival patient treat regimen . - Compare complete response rate patient treat regimen . - Compare tumor control patient treat regimen . - Compare safety regimens patient . - Compare pharmacoeconomics regimen . - Compare patient adherence regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . All patient give option receive 1-week course pretreatment therapy comprise vincristine IV day -6 oral prednisone daily day -6 0 . - Arm I : Patients receive R-CHOP immunochemotherapy comprise rituximab IV , cyclophosphamide IV 15 minute , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisone daily day 1-5 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients undergo restaging disease . Patients disease progression proceed salvage therapy study . All patient receive 3 course R-CHOP . - Arm II : Patients receive R-CHOP arm I . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients undergo restaging disease . Patients disease progression proceed salvage therapy study . All patient receive 1 course R-CHOP follow 2 course rituximab alone . All patient undergo final restaging 6 course rituximab . Patients disease progression , stable disease , partial response proceed salvage therapy study . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 622 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive Bcell nonHodgkin 's lymphoma , include follow subtypes : Grade 3 follicular lymphoma Diffuse Bcell lymphoma , include diffuse large cell lymphoma follow variant : Centroblastic Immunoblastic Plasmablastic Anaplastic large cell Tcellrich Bcell lymphoma Primary effusion lymphoma Intravascular Bcell lymphoma Primary mediastinal Bcell lymphoma Burkitt 's Burkittlike lymphoma Mantle cell lymphoma ( blastoid ) Aggressive marginal zone lymphoma ( monocytoid ) Previously untreated disease CD20positive disease International Prognostic Index ( IPI ) score 0 No bulky disease Largest single conglomerate tumor &lt; 7.5 cm diameter No mucosaassociated lymphoid tissue ( MALT ) lymphoma No CNS involvement lymphoma ( intracerebral , meningeal , intraspinal ) PATIENT CHARACTERISTICS : ECOG performance status 01 Platelet count ≥ 100,000/mm^3 WBC ≥ 2,500/mm^3 Lactate dehydrogenase normal Not pregnant lactate Fertile patient must use effective contraception 1 year study participation Negative pregnancy test No know hypersensitivity study medication No know HIVpositivity No active hepatitis infection No impaired leave ventricular function No severe cardiac arrhythmia No impair organ function No serious disorder No malignancy within past 5 year except carcinoma situ basal cell skin cancer PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No prior immunosuppressive treatment cytostatics No plan radiotherapy extranodal involvement No concurrent participation treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>